youtube_live
Q2 2027 earnings • in 5 days
See detailschevron_right
RDY:NYSE
Dr Reddy's Laboratories Ltd
13,07 $
arrow_upward
+1,32%(+0,17) 1D
13,07 $
0,00% (0,00)
bedtimeAfter hours
Closed: 16 հոկ, 16:00:07 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RDY...
Open
13,00 $
High
13,07 $
Low
12,94 $
Mkt. cap
10,81 մլրդ
Avg. vol.
3,19 մլն
Volume
2,79 մլն
Dividend
0,64%
Quarterly dividend
0,02 $
Ex-dividend date
10 հլս, 2026 թ.
P/E ratio
31,34
52-wk high
15,67 $
52-wk low
11,36 $
EPS
0,42 $
Beta
0,30
Shares outstanding
834,64 մլն
No. of employees
28 հզր
Open
13,00 $
High
13,07 $
Low
12,94 $
Mkt. cap
10,81 մլրդ
Avg. vol.
3,19 մլն
Volume
2,79 մլն
Dividend
0,64%
Quarterly dividend
0,02 $
Ex-dividend date
10 հլս, 2026 թ.
P/E ratio
31,34
52-wk high
15,67 $
52-wk low
11,36 $
EPS
0,42 $
Beta
0,30
Shares outstanding
834,64 մլն
No. of employees
28 հզր
News stories
From web sources and news partners
Capital Brief
·
24 րոպե առաջ
Australian shares to open lower as chip selloff weighs on Nasdaq
Yahoo Finance
·
12 ժամ առաջ
Michael Burry Warns of a Stock Market ‘Supervolcano’
MarketWatch
·
7 ժամ առաջ
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 հզր
Founded1984
HeadquartersՀայդերաբադ, Անդհրա-Պրադեշ, Հնդկաստան
Sector-
Websitedrreddys.com